葡萄糖激酶
胰岛素
作用机理
药效学
药品
药理学
激活剂(遗传学)
碳水化合物代谢
糖尿病
糖耐量试验
医学
内分泌学
内科学
化学
药代动力学
胰岛素抵抗
体外
生物化学
受体
作者
Petra M. Jauslin,Mats O. Karlsson,Nicolas Frey
标识
DOI:10.1177/0091270011422231
摘要
A mechanistic drug-disease model was developed on the basis of a previously published integrated glucose-insulin model by Jauslin et al. A glucokinase activator was used as a test compound to evaluate the model's ability to identify a drug's mechanism of action and estimate its effects on glucose and insulin profiles following oral glucose tolerance tests. A kinetic-pharmacodynamic approach was chosen to describe the drug's pharmacodynamic effects in a dose-response-time model. Four possible mechanisms of action of antidiabetic drugs were evaluated, and the corresponding affected model parameters were identified: insulin secretion, glucose production, insulin effect on glucose elimination, and insulin-independent glucose elimination. Inclusion of drug effects in the model at these sites of action was first tested one-by-one and then in combination. The results demonstrate the ability of this model to identify the dual mechanism of action of a glucokinase activator and describe and predict its effects: Estimating a stimulating drug effect on insulin secretion and an inhibiting effect on glucose output resulted in a significantly better model fit than any other combination of effect sites. The model may be used for dose finding in early clinical drug development and for gaining more insight into a drug candidate's mechanism of action.
科研通智能强力驱动
Strongly Powered by AbleSci AI